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Abstract 
Objectives:  To evaluate the activity of two different taurolidine (TAU) gels in comparison with 
a 0.2% chlorhexidine (CHX) gel on an ex-vivo subgingival biofilm.   
Material and Methods: Subgingival incl. supragingival biofilm samples from periodontitis 
patients were cultured for 10 d, before TAU 1% and TAU 3% gels and CHX gel were applied 
for 10 min and thereafter diluted with nutrient media to 10% for 50 min. One third of the samples 
was analyzed for bacterial counts, biofilm quantity and biofilm metabolic activity. In the two 
other thirds, 90% of the nutrient media were replaced and biofilms were incubated for 23 h. 
The second third was analyzed in the same way as before. In the third part patients’ 
microorganisms were added again and incubated for additional 24 h to allow reformation of 
biofilm before proceeded to analysis.  
Results: Decrease of bacterial counts in biofilms was highest following application of TAU 3% 
after 60 min (0.87 log10 cfu, corresponding 86.5%), 24 h and 48 h (reformation of biofilms), 
respectively. All antimicrobials reduced biofilm quantity after 24 h (each p<0.05) and following 
reformation of biofilms (each p<0.01). Metabolic activity in biofilms was decreased at 60 min 
(each p<0.05) and at 24 h (each p<0.01) after application of TAU gels, while the activity of the 
reformed biofilm was lower after application of all evaluated antimicrobials (each p<0.01) than 
in the control group (e.g. without exposure to antimicrobials).  
Conclusion: The antimicrobial activity of taurolidine gels clearly depends on its taurolidine 
concentration. A high concentrated taurolidine gel is equally active or even superior to 0.2% 
chlorhexidine gel. However, the activity of antimicrobials is limited in a complex established 
biofilm and underlines the pivotal role of mechanical biofilm disruption.  
Clinical relevance: Within their limits, the data suggest that TAU 3% gel might represent a 
potential alternative to 0.2% chlorhexidine gel.   
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Introduction 
Periodontitis is an inflammatory oral disease in response to oral biofilm which affects and 
destroys the tooth`s supporting tissues leading finally to tooth loss. The etiology of periodontitis 
is that microbiota in subgingival biofilm including Porphyromonas gingivalis, Aggregatibacter 
actinomycetemcomitans, Tannerella forsythia, Treponema denticola induces innate, 
inflammatory and adaptive host response [1]. Certain microorganisms, e.g. P. gingivalis may 
act as key-stone pathogens by changing a symbiotic microbiota into a dysbiotic one via 
modifying host response [2].   
The key step of periodontal therapy consists of the removal of supra- and subgingival bacterial 
biofilm [3]. A systematic review showed that improvement of clinical attachment level is 
primarily achieved by mechanical non-surgical therapy [4], the use of antimicrobials are 
generally recommended for additional use [5]. In dentistry, chlorhexidine is one of the best 
documented antimicrobial agents [6]. Chlorhexidine is active against most microbial species 
[7, 8], but it is also cytotoxic [9, 10]. Moreover, discoloration, taste irritation  occur frequently 
after application of various chlorhexidine-containing formulations [11, 12]. Substantial data 
indicate that the use of adjunctive systemic antibiotics appears to be beneficial in advanced 
and severe cases to arrest the bacterial biofilm caused infection and subsequent inflammation 
[13]. However, the long-term clinical benefit following the use of antibiotics is still unclear and 
needs to be carefully considered, especially in the light of the global increase of antibiotic 
resistance [14, 15]. Therefore, the use of systemic antibiotics in the treatment of periodontal 
infections should be carefully considered and obviously, there is a clear need for alternative 
antimicrobial agents.  
Taurolidine is most discussed as a lock solution for central venous catheters because of its 
antibacterial and antibiofilm properties [16].  Antimicrobial activity was described against gram-
positive and gram-negative bacteria as well as against Candida spp. [17]. It exerts its activity 
by inactivating endotoxin in gram-negative bacteria [18] and interacting with peptidoglycan 
[19].   
Taurolidine appears to be a potential alternative also in dentistry. Several years ago, a potential 
antimicrobial activity of taurolidine was reported against oral microorganisms [20, 21]. 
Recently, our group has shown that 2% taurolidine is effective in killing supragingival plaque 
[22]. In earlier studies, the MICs of taurolidine against oral species were determined as all 
below 5% of the normally used concentration of that substance with the exception of Candida 
albicans [23]. Moreover, previous data from a series of studies performed in our laboratory 
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have shown that taurolidine solutions and taurolidine gels inhibited clearly the formation of 
defined biofilms containing laboratory strains [24, 25].       
Therefore, the aim of the present study was to determine the activity of two different taurolidine 
gels as compared with a 0.2% chlorhexidine gel on an ex-vivo subgingival biofilm formed for 
10 d and on its reformation including the assessment of the killing of bacteria within the biofilm, 
of the biofilm quantity and of the biofilm metabolic activity.   
 
Material and methods 
Sampling from chronic periodontitis patients 
The Ethical Committee of the Canton Bern approved the study protocol (KEK 035/2015). After 
signing the informed consent form, biofilm samples were obtained from nine patients with 
advanced chronic periodontitis referred to the Department of Periodontology, University of 
Bern, School of Dental Medicine. 
For inclusion in the study, the following criteria had to be fulfilled: probing depths (PD) of ≥5 
mm at least at four non adjacent sites and presence of at least two of the main four bacterial 
species associated with periodontal disease: A. actinomycetemcomitans, P. gingivalis, T. 
denticola and T. forsythia detected via routinely used microIdent® test (Hain Lifescience, 
Nehren, Germany). Exclusion criteria were: intake of antibiotics three months prior to the study, 
periodontal therapy within the last six months, diabetes or other severe systemic disorders 
affecting the immune system.   
Patients were asked to refrain from oral hygiene for 24 h in the areas where plaque was to be 
sampled. The deepest pockets per quadrant were selected. Without removing supragingival 
plaque each two paper-points (ISO 055) were inserted until resistance was felt. After 30 s, the 
paper points were removed, transferred into tubes containing 1 ml of transport media (reduced 
transport fluid (RTF)) [26], and proceeded immediately to the laboratory where they were kept 
at 4°C 
In addition, about 2 ml of non-stimulated saliva were collected from each individual and 
centrifuged at 500 g for 10 min.  
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Antimicrobials  
The antimicrobials to be tested were taurolidine in 1% (w/w) and 3% (w/w) gel formulation 
(1% PerioSept Gel, 3% PerioSept Gel, both Geistlich Pharma AG, Wolhusen, Switzerland). 
A 0.2% (w/w) chlorhexidine gel (Plak-Out Gel (Kerr-Hawe SA, Bloggio, Switzerland) as a 
positive control and dH2O as a negative control were be included in addition.   
 
Ex-vivo biofilm model 
The ex-vivo model was modified to that described by Walker & Sedlacek [27].   
Biofilms were cultured for each of the nine included patients separately. The day before starting 
biofilm formation, wells of 96-well plates (24-well plates containing glass slides for live-dead 
staining) had been prepared by coating with poly-L-lysine (1 : 10 diluted with dH2O) overnight. 
After removing the non-attached poly-L-lysine solution, supernatants of the patient’s own saliva 
mixed 1 : 1 with phosphate buffered saline (PBS) containing 50% of inactivated human serum 
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) (10 µl 96-well-plate; 55 µl 24-well plate) 
were added and exposed to UV for 30 min and left in place. Meanwhile bacteria were 
suspended in RTF by vortexing and ultrasonication. An amount of 0.5 ml of RTF with bacteria 
was mixed with 19.5 ml of nutrient broth (Wilkins Chalgren broth (Oxoid, Basingstoke, GB) 
containing 5 µg/ml NAD and 5 µg/ml thiamine pyrophosphate (Sigma-Aldrich Chemie GmbH). 
Thereafter, 150 µl (1000 µl when using 24-well-plates) of the suspension was added to each 
well. Biofilms were incubated for 10 d in an anaerobic atmosphere (85% N2, 10% H2, 5% CO2 
in an anaerobic workstation (DG250, Don Whitley Scientific Ltd., Shipley, UK). Nutrient broth 
was exchanged every second day. 
After careful removing the nutrient media, 20 µl (110 µl when using 24-well-plates) of the 
undiluted test substances (concentration of 100%) were given to biofilms. After 10 min, nutrient 
broth was added in a ratio 1 : 9 leading to a concentration of 10% of the substance in the 
media. After 60 min, media was removed and the biofilms were carefully rinsed in one third of 
the wells. Here, counts of bacteria, metabolic activity of biofilm, live-dead ratio and biofilm 
quantity (amount of matrix) were determined thereafter.  
In the two other thirds of the wells, 90% of the nutrient media were exchanged by fresh ones 
(concentration of 1% of the substance in the medium). After an additional incubation of 24 h, 
procedure (without live-dead ratio) was as after 60 min in the second third.  
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From the last third of wells, the nutrient media was removed. After careful washing, 0.5 ml of 
RTF with bacteria (which were kept at -80°C) mixed with 19.5 ml of nutrient broth were added 
for an additional incubation of 24 h to assess the antimicrobials’ influence on reformation of 
biofilm (recolonization). Thereafter at 48 h, samples were analyzed as for the time-point 24 h.    
 
Analyses of biofilms 
Bacterial counts were determined by enumeration of total colony forming units (cfu) after 
scraping the biofilm from the surface, extensive mixing, making a serial dilution and plating 
25 µl each on tryptic soy agar plates with 5% of sheep blood and anaerobic cultivation for 10 
d. In addition, 16S rDNA analysis (real-time PCR) was made for the presence of major 
species being associated with periodontitis (P. gingivalis, T. forsythia, T. denticola and A. 
actinomycetemcomitans) by using GoTaq qPCR Master Mix (Promega Corporation, 
Madison, WI, USA), as described recently [28].  
 
Quantification of the biofilms was made according to recently published protocols [29]. After 
rinsing, the biofilms were fixed at 60°C for 60 min. Thereafter, biofilms were stained with 50 µl 
per well 0.06% (w/v) crystal violet (Sigma-Aldrich Chemie GmbH) for 10 min and the staining 
was quantified by using a plate reader (ELx808, Biotek Instruments, Winooski, VT, USA) at 
600 nm. 
Biofilm metabolic activity was assessed with using Alamar blue as a redox indicator [30]. Five 
µl of Alamar blue (alamarBlue® reagent, Thermo Fisher Scientific Inc., Waltham, MA, USA) 
was mixed with 100 µl of the nutrient media and added to the biofilm. After extensive mixing 
with the biofilm and an incubation for 1 h at 37°C, ratio of absorbances at 600 nm and 570 nm 
were calculated after measuring by using a microplate reader (ELx808, Biotek).  
Biofilms formed on glass slides in 24-well-plates and proceeded as described above (treatment 
with antimicrobials, rinsing), were stained and visualized with live-dead staining (Live/dead® 
BacLight™ Bacterial Viability kit, Invitrogen Corporation, Carlsbad, CA, USA) by using a 
fluorescent microscope (Olympus BX51, Tokyo, Japan) with the settings excitation 460-495 
nm, emission 510-550 nm, mirror 505 nm for Cyto 9 dye and excitation 530-550 nm, emission 
575-625 nm, mirror 570 nm for propidium iodide. Ratio between live and dead bacteria was 
related to the means of green or red color mean intensity by using Adobe® Photoshop@ 
Elements 9.0 software (Adobe Systems, Mountain View, CA, USA). This analysis was made 
only at the time-point 60 min.  
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Statistical methods  
Biofilm samples per patient were always assayed in independent duplicates, meaning in a total 
18 samples were analyzed per group each. ANOVA with Post-Hoc LSD was used for statistical 
analysis. The level of significance was set to p=0.05. Software SPSS 22.0 (IBM SPSS 
Statistics, Chicago, IL, USA) was used.    
 
Results 
Microbial counts 
The cfu counts in biofilms without exposure to antimicrobials were 7.68±0.19 log10 cfu after 
10 d (60 min), 7.88±0.25 log10 cfu after 11 d (24 h) and 8.60±0.61 after 12 d (48 h, 24 h of 
reformation of biofilm; p<0.001 vs. 60 min, 24 h). Sixty minutes after exposing the biofilms to 
any of the antimicrobials, the counts in biofilms were significantly reduced (TAU 1%: reduction 
0.36 log 10 cfu, p=0.021; TAU 3%: reduction 0.87 log10 cfu, p<0.001 and CHX 0.2%: reduction 
0.64 log 10 cfu, p<0.001), however the difference was at the highest 0.87 log10 cfu (TAU 3%) 
(corresponding to 86.5% reduction). TAU 3% was significantly more active than TAU 1% 
(p=0.001). After 24 h exposure, differences to control were still significant for TAU 3% (-0.58 
log10, p<0.001) and for CHX 0.2% (-0.47 log10, p=0.001). Only TAU 3% was able to inhibit 
significantly reformation of biofilms (difference: -0.61 log10, p=0.004) (Fig. 1).  
Samples being initially tested positively for the analyzed species were included in the nucleic-
acid based analysis of single species. P. gingivalis was detected in seven, A. 
actinomycetemcomitans in three and T. denticola in two of the nine patients. All biofilm control 
samples had been positively tested for T. forsythia. Counts of P. gingivalis and T. denticola 
were reduced after 60 min exposure to TAU 3% (p=0.036, p=0.022) and CHX 0.2% (p=0.020, 
p=0.023). In reformed biofilm the counts were less for T. forsythia after TAU 3% (p=0.017) and 
for all analyzed species after CHX 0.2% (P. gingivalis: p=0.022, T. forsythia: p=0.039, T. 
denticola: p=0.003, A. actinomycetemcomitans: p=0.012) than in the controls (Fig. 2).    
The live/dead ratio 60 min after antimicrobial exposure showed a decrease after CHX 0.2% 
treatment compared to control (p=0.006) and to TAU 1% (p=0.011; Fig. 3).  
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Biofilm quantity and metabolic activity 
All treatments significantly reduced biofilm quantity after 24 h (TAU 3%: p=0.023, TAU 1%: 
p=0.028, CHX 0.2%: p=0.012) and after 48 h (reformation of biofilms for 24 h) (each p<0.001). 
There was no difference between the antimicrobials (Fig. 4).   
Metabolic activity in biofilms was significantly reduced 60 min after TAU 3% (p=0.016) and 
TAU 1% (p=0.026) and 24 h after TAU 3% (p=0.002) and TAU 1% (p=0.004). The metabolic 
activity of the reformed biofilm was always lower after any antimicrobials application than in 
the control without exposure to antimicrobials (TAU 3% and TAU 1%: p<0.001, CHX 0.2%: 
p=0.001; Fig. 5) 
 
Discussion 
The purpose of the present in vitro study was to evaluate the activity of taurolidine gels on an 
ex-vivo biofilm generated from periodontitis patients’ samples.    
Samples including primarily subgingival but also supragingival biofilm were obtained from 
periodontitis patients that harbored bacteria associated with periodontal disease. Sampling 
method was in accordance with those used for routine microbiological analysis. It is based on 
a report that without removing supragingival biofilm the detection rate of bacterial species being 
associated with periodontitis is higher [31]. Subsequently, the plaque samples were used to 
form an ex-vivo biofilm. The modifications of the model described by Walker & Sedlacek [27] 
include the use of native saliva without any sterile filtration and the repeated addition of 
subgingival plaque samples to mimic reformation. The rationale for using native saliva is to 
ensure its unchanged protein composition, since it has been shown that filtering decreases the 
protein content and modifies the protein composition [32]. The results revealed consistently 
higher bacterial counts and higher biofilm quantity and metabolic activity in the reformed than 
in the first formed biofilm, thus confirming successful incorporation of these microorganisms in 
the biofilms. 
In the present study a complex biofilm was formed and treated with antimicrobials. Subsequent 
analyses were performed by several methods. Ex vivo oral biofilms were occasionally used for 
determining activity of antimicrobials. Four hours – 10 days old biofilms had been exposed to 
antibiotics for 48 h [33]. The activity of chlorhexidine was compared with photodynamic therapy 
9 
 
on biofilms cultured for 24 h and 72 h [34]. Oral antiseptics (e.g. mouth rinses) were tested to 
inhibit salivary biofilm formation [35]. Sometimes, plaque samples are harvested and directly 
exposed to potential antimicrobials in the laboratory [36, 37].  
Teeth are surrounded by a continuous flow of gingival crevicular fluid [38]. In order to simulate 
the in vivo situation, the applied antimicrobial was diluted to 10% after 10 min and in part 
additionally after 60 min to 1%. The highest reduction of bacterial counts after the application 
of antimicrobials was 86.5%. However, a killing activity of an antimicrobial is generally defined 
as a reduction by at least 3 log10 over a defined time, here only 0.87 log10 were reached. In 
our previously performed study using a defined 12-species biofilm, the same antimicrobial 
(TAU 3%) reached 3.63 log10,  [25]. There 3% taurolidine has been in contact with the biofilm 
for 60 min before diluting to 0.3%, in the present study dilution was already after 10 min to 
0.3%.   
Comparing TAU 3% with TAU 1% a clear concentration dependent activity was visible on total 
bacterial counts (cfu) as well as on selected species (P. gingivalis and T. denticola after 60 
min) in biofilm. This is in agreement with findings from previous studies using a 12-species 
biofilm, where higher concentrations of taurolidine solutions [24] and taurolidine gels [25] were 
more bactericidal than lower ones. However, in the present study, there was no difference 
between the two taurolidine gels regarding biofilm quantity and metabolic activity. Both gels 
decrease biofilm metabolic activity already after 60 min, thus suggesting that a lower 
concentration of taurolidine may already inhibit bacterial metabolism. Biofilm quantity 
determined by crystal violet staining is reduced after 24 h. Biofilms are not only bacteria, they 
consist of self-produced matrix of extracellular polymeric substances [39]. Interference with 
bacterial matrix components is an approach in the development of anti-biofilm drugs [40]; 
investigating this aspect in more detail might be of interest in further research. An activity of 
the vehicle used in taurolidine gels on biofilm metabolic activity and biofilm quantity cannot be 
ruled out. In our previous study [25] no influence of the vehicle on bacterial counts was seen. 
Due to the complexity of the study design, a vehicle could not be included.  
In the present study, TAU 3% reduced as CHX 0.2% total bacterial counts (cfu) in biofilm after 
60 min and 24 h. Although the reduction of percentage of viable bacteria related to dead 
bacteria failed to show statistical significance for TAU 3% in contrast to CHX 0.2%, there was 
no statistical significant difference between the two antimicrobials. TAU 3% was the only tested 
compound showing a very small, but statistically significantly different reduction of total 
bacterial counts (cfu) in the reformed biofilm. These findings are of particular interest, 
especially in comparison with chlorhexidine, a compound with known high substantivity [41].   
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Taken together the available data indicate that taurolidine is a potential alternative as an 
antimicrobial. It interacts with bacterial cell wall components [19] while in long-term users no 
decreased susceptibility of bacteria causing blood-stream infections was observed [42]. Beside 
of its antimicrobial activity taurolidine inhibits the expression of pro-inflammatory cytokines [43]. 
In an animal model there was no toxicity found [44], in in-vitro assays cytotoxicity was 
comparable to other agents like 3% hydrogen peroxide [45] or chlorhexidine [46].    
However, the number of studies investigating the antibacterial properties of taurolidine on oral 
biofilms is still low. Besides the few studies focusing on supra- and subgingival biofilm [22, 24, 
25] it was found, that in contrast to chlorhexidine, the antimicrobial activity of taurolidine is not 
affected in a serum rich environment [23]. Furthermore, a recent in vitro study showed, that 
taurolidine might enhance effectiveness of plaque removing procedures on titanium surfaces 
with plastic curettes and glycine powder airflow [47]. Interestingly, in simulated endodontic 
infections, taurolidine was more bactericidal than chlorhexidine but less than calcium hydroxide 
against Enterococcus faecalis biofilm [46]. 
All these findings appear to suggest that taurolidine may be a potentially relevant antimicrobial 
agent for an adjunctive use to scaling and root planning in the treatment of periodontal pockets. 
Since none of the currently available instrumentation techniques can completely remove the 
supra- and subgingival biofilm [48], the use of adjunctive antimicrobial substances may be of 
potential benefit [49]. Nevertheless, it should be kept in mind that in the present in-vitro study, 
the reduction of bacterial counts in biofilm never exceeded one log10 which in turn, underlines 
once more the fact that antimicrobials alone are not able to completely destroy an already 
established complex biofilm. Therefore, the use of antimicrobials can only be recommended in 
conjunction with mechanical biofilm disruption suggesting once more that mechanical biofilm 
removal is still the gold standard in the therapy of periodontitis [50].   
In summary, the present study has shown that: (i) an ex-vivo biofilm model that closely 
resembles the in vivo situation and enables the evaluation of various antimicrobials can be 
predictably established; (ii) the activity of antimicrobials is limited in a complex established 
biofilm; (iii) the antimicrobial activity of taurolidine gels clearly depends on its active compound 
concentration; (iv) 3% taurolidine gel appears to be an interesting alternative to chlorhexidine 
as an adjunct in periodontal therapy and warrants further evaluation in clinical settings.   
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Figure legends 
Fig. 1 Total counts of colony forming units (cfu) in biofilm 60 min and 24 h as well as after 48 
h (allowing reformation of biofilm for 24 h) after exposing biofilms to undiluted 0.2% 
chlorhexidine (CHX) gel or 1% and 3% taurolidine (TAU) gels for 10 min and a following dilution 
to 10% of the gels (0.02% CHX, 0.1% TAU, 0.3% TAU)  
*p<0.05; **p<0.01 compared to control  
**p<0.01 compared to TAU 3%  
*p<0.05 compared to TAU 1% 
 
Fig. 2 Counts of selected bacterial species in biofilm 60 min and 24 h as well as after 48 h 
(allowing reformation of biofilm for 24 h) after exposing biofilms to undiluted 0.2 % 
chlorhexidine (CHX) gel or 1% and 3% taurolidine (TAU) gels  for 10 min and a following 
dilution to 10% of the gels (0.02% CHX, 0.1% TAU, 0.3% TAU)  
  
*p<0.05; **p<0.01 compared to control  
*p<0.05; **p<0.01 compared to TAU 1% 
 
Fig. 3 Live/dead ratio in biofilms 60 min after exposing biofilms to undiluted 0.2 % 
chlorhexidine (CHX) gel or 1% and 3% taurolidine (TAU) gels for 10 min and a following dilution 
to 10% of the gels (0.02% CHX, 0.1% TAU, 0.3% TAU)  
    
**p<0.01 compared to control  
*p<0.05 compared to TAU 1% 
 
Fig. 4  Biofilm quantity expressed in extinction units at 594 nm after crystal violet staining in 
biofilm 60 min and 24 h as well as after 48 h (allowing reformation of biofilm for 24 h) after 
exposing biofilms to undiluted 0.2 % chlorhexidine (CHX) gel or 1% and 3% taurolidine (TAU) 
gels for 10 min and a following dilution to 10% of the gels (0.02% CHX, 0.1% TAU, 0.3% TAU)  
   
*p<0.05; **p<0.01 compared to control  
 
Fig. 5  Biofilm metabolic activity expressed as ratios of extinction units at 595/570 nm in biofilm 
60 min and 24 h as well as after 48 h (allowing reformation of biofilm for 24 h) after exposing 
biofilms to undiluted 0.2 % chlorhexidine (CHX) gel or 1% and 3% taurolidine (TAU) gels for 
10 min and a following dilution to 10% of the gels (0.02% CHX, 0.1% TAU, 0.3% TAU)  
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*p<0.05; **p<0.01 compared to control  
*p<0.05 compared to TAU 3%  
*p<0.05 compared to TAU 1% 
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